Payment overview · 2025
General Payments
$9,083.30
142 reported records · 42 companies
Healthcare provider profile · identity verified
John George Knecht, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · WEBSTER, TX · NPI 1639360829
Verified facts
What the public records show
CMS Open Payments records show John George Knecht, MD received $9,083.30 in general payments during 2025 across 142 reported records.
Regeneron Pharmaceuticals, Inc. accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 67 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Enhertu, Inqovi, Jakafi, Keytruda.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENHERTU as an associated drug or biological on 13123 records involving 6425 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Enhertu by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
Daiichi Sankyo Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Enhertu as an associated drug or biological on 25710 records involving 8530 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Enhertu by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Keytruda by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
TAIHO ONCOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INQOVI as an associated drug or biological on 4572 records involving 2852 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Inqovi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,588.00 | 28.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,870.16 | 20.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $438.99 | 4.8% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $347.72 | 3.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $303.13 | 3.3% | 10 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $275.12 | 3.0% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $265.42 | 2.9% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $256.55 | 2.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $250.15 | 2.8% | 10 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $241.11 | 2.6% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $231.11 | 2.5% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $210.10 | 2.3% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $196.58 | 2.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.18 | 1.8% | 7 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $155.03 | 1.7% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $143.74 | 1.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.21 | 1.6% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $124.64 | 1.4% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $90.15 | 1.0% | 4 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $74.99 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $67.67 | 0.7% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.57 | 0.7% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $51.10 | 0.6% | 2 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.50 | 0.5% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $43.04 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.97 | 0.5% | 2 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.35 | 0.3% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $30.54 | 0.3% | 2 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $29.93 | 0.3% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.20 | 0.3% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.70 | 0.3% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $28.04 | 0.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $27.44 | 0.3% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $25.33 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.08 | 0.3% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $24.47 | 0.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.07 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.27 | 0.3% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $21.29 | 0.2% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $20.91 | 0.2% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $17.47 | 0.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.28 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,537.13 | 132 |
| Consulting Fee | $4,238.00 | 4 |
| Education | $308.17 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Pharmaceuticals, Inc. | $2,588.00 | 3 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $328.75 | 7 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $272.10 | 7 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $250.15 | 10 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $225.72 | 3 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $219.75 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $186.48 | 8 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $155.03 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $143.74 | 4 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $142.21 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $141.67 | 7 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $134.69 | 3 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $132.98 | 2 | 2025 |
Source payment records
|
|||||
| SYLVANT Normalized: sylvant |
Drug | RECORDATI_RARE_DISEASES_INC. | $124.64 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $124.00 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $110.85 | 5 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $108.13 | 4 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $93.24 | 4 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $90.15 | 4 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $90.15 | 4 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $87.33 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $67.67 | 3 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $66.33 | 4 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $65.49 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $63.57 | 3 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $55.37 | 3 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $48.50 | 1 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $34.24 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $32.33 | 1 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $31.35 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $29.20 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $29.09 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| KRAZATI Normalized: krazati |
Drug | E.R. Squibb & Sons, L.L.C. | $9.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Enhertu enhertu |
2025 | Enhertu | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INQOVI inqovi |
2025 | Inqovi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ENHERTU open payments reported associated product |
CMS Open Payments — General Payments 13123 supporting records · 6425 recipient NPIs · example record 1206131386 |
Enhertu · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 30 |
| Daiichi Sankyo Inc. Exact reporting entity; no affiliate inference |
2025 | Enhertu open payments reported associated product |
CMS Open Payments — General Payments 25710 supporting records · 8530 recipient NPIs · example record 1197002051 |
Enhertu · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 30 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 30 |
| TAIHO ONCOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | INQOVI open payments reported associated product |
CMS Open Payments — General Payments 4572 supporting records · 2852 recipient NPIs · example record 1211403676 |
Inqovi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 127 | 30 |
| Anastrozole | Anastrozole | 110 | 31 |
| Xarelto | Rivaroxaban | 57 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 13 |
| Jakafi | Ruxolitinib Phosphate | 43 | suppressed |
| Procrit | Epoetin Alfa | 43 | suppressed |
| Metformin Hcl | Metformin Hcl | 35 | suppressed |
| Furosemide | Furosemide | 32 | 13 |
| Keytruda | Pembrolizumab | 29 | suppressed |
| Gabapentin | Gabapentin | 27 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | 12 |
| Fluorouracil | Fluorouracil | 25 | suppressed |
| Zoledronic Acid | Zoledronic Acid | 25 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 23 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 23 | suppressed |
| Inqovi | Decitabine/Cedazuridine | 22 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 21 | suppressed |
| Brukinsa | Zanubrutinib | 20 | suppressed |
| Dexamethasone | Dexamethasone | 19 | suppressed |
| Abraxane | Paclitaxel Protein-Bound | 18 | suppressed |
| Paclitaxel | Paclitaxel | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Everolimus | Everolimus | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Enhertu | Fam-Trastuzumab Deruxtecn-Nxki | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Irinotecan Hcl | Irinotecan Hcl | 15 | suppressed |
| Oxaliplatin | Oxaliplatin | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Revlimid | Lenalidomide | 13 | suppressed |
| Rituxan | Rituximab | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,083.30 · 142 records | Regeneron Pharmaceuticals, Inc. | ACCRUFER, ADCETRIS, BESREMI, BLENREP, BREYANZI, BRUKINSA, CARVYKTI, DANZITEN, DATROWAY, ELREXFIO, EPKINLY, ERLEADA, Enhertu, FOTIVDA, FRUZAQLA, Fabhalta, Gavreto, IBRANCE, IMBRUVICA, IMFINZI, INLYTA, INQOVI, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KISQALI, KRAZATI, LIBTAYO, LONSURF, LYNPARZA, Lenvima, MONJUVI, NERLYNX, Nubeqa, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Orserdu, PADCEV, PROVENGE, REBLOZYL, REVUFORJ, RUCONEST, RYBREVANT, Rezlidhia, SARCLISA, SCEMBLIX, SYLVANT, TALZENNA, TAVALISSE, TERIPARATIDE, TUKYSA, Trelstar, Trodelvy, VERZENIO, Vonjo, Vyloy, WELIREG, XPOVIO, XTANDI, Xofigo, Xospata, ZEJULA, ZEPZELCA, clonoSEQ | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error